SAGE Quote, Financials, Valuation and Earnings

IGM Biosciences has a net margin of -442.4% compared to Sage Therapeutics's net margin of -10599.6%. Sage Therapeutics's return on equity of -64.19% beat IGM Biosciences's return on equity of -241.68%.

Sage Therapeutics has a consensus price target of $8.73, signalling downside risk potential of -4.4%. On the other hand IGM Biosciences has an analysts' consensus of $1.12 which suggests that it could fall by -11.54%. Given that IGM Biosciences has more downside risk than Sage Therapeutics, analysts believe Sage Therapeutics is more attractive than IGM Biosciences.

Sage Therapeutics has a beta of 0.294, which suggesting that the stock is 70.557% less volatile than S&P 500. In comparison IGM Biosciences has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.552%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGM Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. IGM Biosciences pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are larger than IGM Biosciences quarterly revenues of $499K. Sage Therapeutics's net income of -$62.2M is lower than IGM Biosciences's net income of -$52.9M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while IGM Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.79x versus 28.79x for IGM Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -442.4% compared to Sage Therapeutics's net margin of 21.68%. Sage Therapeutics's return on equity of -64.19% beat Eli Lilly and's return on equity of 78.25%.

Sage Therapeutics has a consensus price target of $8.73, signalling downside risk potential of -4.4%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Eli Lilly and has higher upside potential than Sage Therapeutics, analysts believe Eli Lilly and is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.294, which suggesting that the stock is 70.557% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Sage Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sage Therapeutics quarterly revenues are $14.1M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Sage Therapeutics's net income of -$62.2M is lower than Eli Lilly and's net income of $2.8B. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.79x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -442.4% compared to Sage Therapeutics's net margin of -60.08%. Sage Therapeutics's return on equity of -64.19% beat Sarepta Therapeutics's return on equity of -20.94%.

Sage Therapeutics has a consensus price target of $8.73, signalling downside risk potential of -4.4%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.54 which suggests that it could grow by 144.39%. Given that Sarepta Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.294, which suggesting that the stock is 70.557% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Sage Therapeutics's net income of -$62.2M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.79x versus 0.91x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of -442.4% compared to Sage Therapeutics's net margin of -7.89%. Sage Therapeutics's return on equity of -64.19% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Sage Therapeutics has a consensus price target of $8.73, signalling downside risk potential of -4.4%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 16.35%. Given that Supernus Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe Supernus Pharmaceuticals is more attractive than Sage Therapeutics.

Sage Therapeutics has a beta of 0.294, which suggesting that the stock is 70.557% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.700, suggesting its less volatile than the S&P 500 by 30.01%.

Sage Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sage Therapeutics pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Sage Therapeutics quarterly revenues are $14.1M, which are smaller than Supernus Pharmaceuticals quarterly revenues of $149.8M. Sage Therapeutics's net income of -$62.2M is lower than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Sage Therapeutics's price-to-earnings ratio is -- while Supernus Pharmaceuticals's PE ratio is 30.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sage Therapeutics is 11.79x versus 2.81x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.